Amarin Corporation, a clinical-stage biopharmaceutical company, has appointed John Thero as chief financial officer (CFO). In this role, he will have broad responsibility for financial and administrative matters of the company and be actively involved in corporate development and other strategic and operational matters. He will report directly to Dr. Declan Doogan, Amarin’s interim chief executive officer (CEO).
Thero has more than 20 years of senior financial and operational management experience, including over 15 years supporting the growth of life science companies. Previously, he was CFO at ViaCell, where he helped guide the company to its successful sale, and Abiomed, during its transition from a development-stage company into a commercial entity. Thero began his professional career at Arthur Andersen, during which time he became a certified public accountant (CPA).
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.